Cancer Research Technology
Log in Register
Menu

Anti-eAg Antibody from X63 Fused CD19 B Cell Hybridoma (D4)

Invented by Anders Elm Pedersen, Mogens H Claesson

Info

Catalogue Number 153818
Applications N/A
Antigen/Gene or Protein Targets Enteroantigen
Reactivity N/A
Relevance Regulatory B cells (Bregs) have been shown to play a role in inflammatory bowel disease (IBD) in humans, as B cell depletion in patients with IBD tends to aggravate the disease. Furthermore it has been demonstrated that co-transfer of eAg-exposed B cells improves symptoms of experimental colitis in the T cell transfer model of colitis.

This eAg-specific B cell hybridoma offers a unique tool to investigate the immune response towards eAg’s in experimental colitis, and potentially, in human IBD.
Notes Hybridoma cell lines profit from the addition of 10 ng/ml of human IL-6 in the growth media.
Research Area Other

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

In vitro cloning and regulatory potential of B cell hybridomas secreting entero-antigen specific antibody.


Add a reference

References: 1 entry

In vitro cloning and regulatory potential of B cell hybridomas secreting entero-antigen specific antibody.


Add a reference

Inventor Information

Inventors

Anders Elm Pedersen

Anders Elm Pedersen

Mogens H Claesson

Mogens H Claesson

Add an inventor